オプションチェーンは、Johnson & Johnsonの株式オプションの主要データを様々な行使価格と満期日で表示します。トレーダーはこの情報を使用して、潜在的な取引を分析し、Johnson & Johnsonの市場センチメントを評価します。.

Johnson & Johnson (NYSE:JNJ) 株価情報, オプションチェーン

Johnson & Johnson

Johnson & Johnson is the world's largest and most diverse healthcare firm. It has two divisions: pharmaceutical and medical devices. These now represent all of the company's sales following the divestment of the consumer business, Kenvue, in 2023. The drug division focuses on the following therapeutic areas: immunology, oncology, neurology, pulmonary, cardiology, and metabolic diseases. Geographically, just over half of total revenue is generated in the United States.

JOHNSON & JOHNSON ORD

Guggenheim analyst Vamil Divan maintains Johnson &amp; Johnson (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/JNJ#NYSE">JNJ</a>) with a Neutral and raises the price target from $156 to $162.

News

Price Target

Analyst Ratings

Guggenheim Maintains Neutral on Johnson & Johnson, Raises Price Target to $162

During times of turbulence and uncertainty in the markets, many investors turn to dividend-yielding stocks. These are often companies that have high free cash flows and reward shareholders with a<a href="https://www.benzinga.com/yield-investments"> high dividend payout</a>.
Benzinga readers can review the latest analyst takes on their favorite stocks by visiting <a href="https://www.benzinga.com/analyst-stock-ratings">Analyst Stock Ratings</a> page. Traders can sort through Benzinga's extensive database of analyst ratings, including <a href="https://www.benzinga.com/analyst-ratings/analyst-color/22/09/28888638/exclusive-study-finds-benzinga-analyst-ratings-data-yields-market-beating-strategie">by analyst accuracy</a>.
Below are the ratings of the most accurate analysts for three high-yielding stocks in the health care sector.
<h3 class="wp-block-heading">Royalty Pharma plc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RPRX#NASDAQ">RPRX</a>)</h3>
<ul>
<li>Dividend Yield: 3.05%</li>
<li>Citigroup analyst Andrew Baum maintained a Buy rating and cut the price target from $60 to $40 on Oct. 25. This analyst has an accuracy rate of 72%.</li>
<li>Morgan Stanley analyst Terence Flynn maintained an Overweight rating and raised the price target from $48 to $51 on July 11. This analyst has an accuracy rate of 69%.</li>
<li>Recent News: On Nov. 4, Royalty Pharma and Syndax Pharmaceuticals entered into $350 million royalty funding agreement for Niktimvo.</li>
<li>Benzinga Pro's real-time newsfeed alerted to l<a href="https://www.benzinga.com/pro/?utm_source=BZprocontent110624&amp;t=be2bearmibe3na1">atest RPRX news. </a></li>
</ul>
<figure class="wp-block-image is-resized"><a href="https://www.benzinga.com/pro/?utm_source=BZprocontent110624&amp;t=be2bearmibe3na1"><img decoding="async" src="blob:https://editorial.benzinga.com/21cac52e-a5a5-4623-954e-111f57f53a6d" alt="" style="width:638px;height:auto" /></a></figure>
<h3 class="wp-block-heading">Johnson &amp; Johnson (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/JNJ#NYSE">JNJ</a>)</h3>
<ul>
<li>Dividend Yield: 3.13%</li>
<li>Citigroup analyst Joanne Wuensch maintained a Buy rating and raised the price target from $180 to $185 on Oct. 16. This analyst has an accuracy rate of 77%.</li>
<li>Wells Fargo analyst Larry Biegelsen maintained an Equal-Weight rating and increased the price target from $163 to $166 on Oct. 16. This analyst has an accuracy rate of 72%.</li>
<li>Recent News: On Oct. 28, Johnson &amp; Johnson announced results from the Phase 3 GRAVITI study of Tremfya (guselkumab) for Crohn's disease.</li>
<li>Benzinga Pro's real-time newsfeed alerted to<a href="https://www.benzinga.com/pro/?utm_source=BZprocontent110624&amp;t=be2bearmibe3na1"> latest JNJ news.</a> </li>
</ul>
<figure class="wp-block-image is-resized"><a href="https://www.benzinga.com/pro/?utm_source=BZprocontent110624&amp;t=be2bearmibe3na1"><img decoding="async" src="blob:https://editorial.benzinga.com/572ca32b-5a3e-4fc3-b873-df0527702e1f" alt="" style="width:659px;height:auto" /></a></figure>
<h3 class="wp-block-heading">Medtronic plc (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MDT#NYSE">MDT</a>)</h3>
<ul>
<li>Dividend Yield: 3.12%</li>
<li>Truist Securities analyst Richard Newitter maintained a Hold rating and raised the price target from $90 to $93 on Oct. 14. This analyst has an accuracy rate of 74%.</li>
<li>Citigroup analyst Joanne Wuensch maintained a Neutral rating and increased the price target from $85 to $92 on Oct. 1. This analyst has an accuracy rate of 77%.</li>
<li>Recent News: Medtronic will report financial results for its second quarter of fiscal year 2025 on Tuesday, Nov. 19.</li>
<li>Benzinga Pro&#8217;s charting tool helped identify the <a href="https://www.benzinga.com/pro/?utm_source=BZprocontent110624&amp;t=be2bearmibe3na1">trend in MDT stoc</a>k. </li>
</ul>
<figure class="wp-block-image size-full is-resized"><a href="https://www.benzinga.com/pro/?utm_source=BZprocontent110624&amp;t=be2bearmibe3na1"><img loading="lazy" decoding="async" width="906" height="841" src="https://editorial-assets.benzinga.com/wp-content/uploads/2024/11/06043120/image-48.png" alt="" class="wp-image-632327" style="width:589px;height:auto" srcset="https://editorial-assets.benzinga.com/wp-content/uploads/2024/11/06043120/image-48.png 906w,https://editorial-assets.benzinga.com/wp-content/uploads/2024/11/06043120/image-48-300x278.png 300w,https://editorial-assets.benzinga.com/wp-content/uploads/2024/11/06043120/image-48-768x713.png 768w" sizes="(max-width: 906px) 100vw, 906px" /></a></figure>
<figure class="wp-block-embed is-type-video is-provider-youtube wp-block-embed-youtube wp-embed-aspect-16-9 wp-has-aspect-ratio"> 
<div class="wp-block-embed__wrapper">
<iframe loading="lazy" title="How to Find Dividend Stocks: Scan, Analyze, and Capture with Benzinga Pro" width="500" height="281" src="https://www.youtube.com/embed/pVF0O2lsEH4?start=1&#038;feature=oembed" frameborder="0" allow="accelerometer; autoplay; clipboard-write; encrypted-media; gyroscope; picture-in-picture; web-share" referrerpolicy="strict-origin-when-cross-origin" allowfullscreen></iframe>
</div>
</figure>
Read More: <a href="https://www.benzinga.com/trading-ideas/long-ideas/24/11/41744659/jim-cramer-says-he-cant-recommend-this-major-automaker-ceva-is-way-too-high">Jim Cramer Says He Can&#8217;t Recommend This Major Automaker, Ceva Is &#8216;Way Too High&#8217;</a>

Dividends

Pre-Market Outlook

Markets

Trading Ideas

RPRX

Wall Street's Most Accurate Analysts Give Their Take On 3 Health Care Stocks With Over 3% Dividend Yields

The global <a href="https://www.benzinga.com/markets/psychedelics">psychedelic drugs market</a> is set for rapid expansion, with projections forecasting growth from $4.88 billion in 2023 to $10.2 billion by 2028, <a href="https://www.einpresswire.com/article/754811757/global-psychedelic-drugs-market-outlook-2024-2033-growth-drivers-share-and-trends">according</a> to The Business Research Company. With a compound annual growth rate of 16.1%, this rise is largely driven by increased awareness of mental health needs, progressive regulatory shifts and the medical community's growing acceptance of <a href="https://www.benzinga.com/topic/psychedelic-assisted-therapies">psychedelics for therapeutic applications</a>.
<h3 class="wp-block-heading">Key Market Drivers: Mental Health Awareness And Regulatory Changes</h3>
The surge in mental health disorders, including <a href="https://www.benzinga.com/topic/treatment-resistant-depression">treatment-resistant depression</a> and <a href="https://www.benzinga.com/topic/ptsd">PTSD</a>, is fueling demand for alternative treatments like psychedelics. "Psychedelic drugs are utilized for treating depression and PTSD, contributing to a decrease in mental health issues," notes The Business Research Company. Psychedelics such as <a href="https://www.benzinga.com/topic/lsd">LSD</a>, <a href="https://www.benzinga.com/topic/ketamine">ketamine</a>, and newer innovations like depression-targeting nasal sprays are becoming prominent options for patients and providers alike.
<h3 class="wp-block-heading">Trends Shaping The Psychedelic Drugs Market</h3>
Key trends include a focus on public education, regulatory adaptation, and diversification of compounds. Companies such as Pfizer (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PFE#NYSE">PFE</a>), Johnson &amp; Johnson (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/JNJ#NYSE">JNJ</a>) and Mydecine Innovations Group (OTC:<a class="ticker" href="https://www.benzinga.com/stock/MYCOF#OTC">MYCOF</a>) are actively advancing in this sector to develop treatments that cater to evolving patient needs. North America currently leads the market, with Asia-Pacific expected to see the fastest growth through 2033 due to increasing <a href="https://www.benzinga.com/markets/cannabis/23/12/36107955/japan-approves-marijuana-derived-medicines-adopt-7-year-prison-sentences-for-recreational-use">policy changes</a> and investment in mental health infrastructure.
<h3 class="wp-block-heading">Market Segmentation: Psychedelic Compounds And Indications</h3>
The market includes various types of psychedelics categorized by drug (LSD, ketamine, GHB), indication (depression, PTSD) and origin (natural or synthetic). Applications range from treatment-resistant depression to panic disorders, with distribution spanning hospitals, retail and online pharmacies.
<h3 class="wp-block-heading">Outlook And Opportunities For Psychedelic Drug Developers</h3>
As research continues to support psychedelics&#8217; benefits in mental health treatment, companies are poised to capitalize on both emerging treatment areas and regional growth opportunities. With major pharmaceutical players investing in these compounds, the market is expected to become increasingly competitive and patient-focused, highlighting a promising outlook for psychedelic treatments.
Cover image made with AI

Cannabis

Psychedelics

Health Care

MYDECINE INNOV GRP by MYDECINE INNOVATIONS GROUP INC.

MYCOF

Global Psychedelic Drugs Market Expected To Reach $10.2B By 2028 Amid Growing Mental Health Crises

GOOG

GOOGL

Hims & Hers Health, Inc. Class A Common Stock

HIMS

Google To Launch New "Sexual Health & Wellness" Policy On November 11, Permitting Promotion Of Personal Lubricants And Prescription Drugs In Select Countries

On Monday, Johnson &amp; Johnson (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/JNJ#NYSE">JNJ</a>) announced results from the Phase 3 GRAVITI study of Tremfya&nbsp;(guselkumab) for Crohn&#8217;s disease.
The findings demonstrated significant clinical remission and endoscopic response at 48 weeks in adults with moderately to <a target="_blank" href="https://www.benzinga.com/pressreleases/24/10/n41570497/tremfya-guselkumab-is-the-first-and-only-il-23-inhibitor-to-demonstrate-robust-results-with-a-full" rel="noreferrer noopener">severely active Crohn&#8217;s disease</a>.
These results are among the 14 Johnson &amp; Johnson abstracts presented at the American College of Gastroenterology 2024.
Also Read: <a target="_blank" href="https://www.benzinga.com/general/biotech/24/10/41552265/johnson-johnsons-blockbuster-drug-tremfya-clears-plaque-psoriasis-with-lesions-covering-bodys-sma" rel="noreferrer noopener">Johnson &amp; Johnson&#8217;s Blockbuster Drug Tremfya Clears Plaque Psoriasis With Lesions Covering Body&#8217;s Smaller Areas</a>.
GRAVITI &nbsp;Subcutaneous Induction Week 12 Results:
<ul>
<li>More than half of patients treated with Tremfya (400 mg administered subcutaneously at Weeks 0, 4, and 8) achieved clinical remission versus those in the placebo group (56.1% versus 21.4%).</li>
<li>Endoscopic response was achieved in 41.3% of patients treated with Tremfya SC induction therapy versus 21.4% in the placebo group.</li>
<li>Greater improvements in clinical remission were seen as early as Week 4 with Tremfya compared with placebo, demonstrating rapid onset of action.</li>
</ul>
GRAVITI SC Induction Week 48 Results:
<ul>
<li>The rate of clinical remission was more than three times higher with both maintenance doses of Tremfya versus placebo (60% for 100 mg SC every eight weeks (q8w) and 66.1% for 200 mg SC every four weeks (q4w) versus 17.1%.</li>
<li>The endoscopic response was achieved in 44.3% and 51.3% of patients in the Tremfya 100 mg SC q8w group and 200 mg SC q4w group, respectively, versus 6.8% in the placebo group.</li>
<li>Endoscopic remission was achieved in 30.4% and 38.3% of patients in the Tremfya 100 mg SC q8w group and 200 mg SC q4w group, respectively, versus 6.0 percent in the placebo group.</li>
</ul>
The FDA approved Tremfya in&nbsp;September 2024&nbsp;for moderately to severely active ulcerative colitis (UC), and an application for moderately to severely active Crohn&#8217;s disease is currently under FDA review.
Regulatory applications seeking approval of Tremfya for moderately to severely active ulcerative colitis and Crohn&#8217;s disease have been submitted in&nbsp;Europe.
Price Action: JNJ stock is up 0.29% at $161.34 at the last check on Monday.
Read Next:
<ul>
<li><a href="https://www.benzinga.com/markets/equities/24/10/41574625/corning-and-at-t-sign-1-billion-deal-to-supercharge-fiber-network" target="_blank" rel="noreferrer noopener">Corning And AT&amp;T Sign $1 Billion+ Deal To Supercharge Fiber Network</a></li>
</ul>
Photo via Shutterstock

Biotech

Large Cap

General

Johnson & Johnson's Tremfya Seeks Expanded Use Approval After It Shares Encouraging Late-Stage Study Data In Crohn's Disease

GRAVITI SC Induction Week 12 Results:
<ul>
<li>More than half of patients treated with TREMFYA (400 mg administered subcutaneously at Weeks 0, 4, and 8) achieved clinical remission versus those in the placebo group (56.1 percent versus 21.4 percent).</li>
<li>Endoscopic response was achieved in 41.3 percent of patients treated with TREMFYA SC&nbsp;induction therapy versus 21.4 percent in the placebo group.</li>
<li>Greater improvements in clinical remission were seen as early as Week 4 with TREMFYA&nbsp;compared with placebo, demonstrating rapid onset of action.</li>
</ul>
GRAVITI SC Induction Week 48 Results:
<ul>
<li>The rate of clinical remission was more than three times higher with both maintenance doses of&nbsp;TREMFYA versus placebo (60.0 percent for 100 mg SC every eight weeks (q8w) and 66.1 percent for 200 mg SC every four weeks (q4w) versus 17.1 percent.</li>
<li>Endoscopic response was achieved in 44.3 percent and 51.3 percent of patients in the&nbsp;TREMFYA 100 mg SC q8w group and 200 mg SC q4w group respectively versus 6.8 percent in the placebo group.</li>
<li>Endoscopic remission was achieved in 30.4 percent and 38.3 percent of patients in the TREMFYA 100 mg SC q8w group and 200 mg SC q4w group respectively versus 6.0 percent in the placebo group.</li>
</ul>

Johnson & Johnson Announced Results From Phase 3 GRAVITI Study Of Tremfya (Guselkumab), Demonstrating Significant Clinical Remission And Endoscopic Response At 48 Weeks In Adults With Moderately To Severely Active Crohn's Disease

On Friday, Johnson &amp; Johnson (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/JNJ#NYSE">JNJ</a>) announced that treatment with Tremfya (guselkumab) resulted in clear or almost clear skin in the majority of adults with low body surface area (BSA) moderate plaque psoriasis (PsO) with special site involvement who had <a target="_blank" href="https://www.benzinga.com/pressreleases/24/10/n41542780/new-spectrem-study-findings-reveal-tremfya-guselkumab-effectively-clears-overlooked-and-undertreat" rel="noreferrer noopener">failed topical treatment</a>.&nbsp;&nbsp;
Data from the Phase 3b SPECTREM study to measure skin clearance and other treatment outcomes in low BSA moderate PsO with involvement across four special sites (scalp, face, skin folds, and genitals) and previous topical treatment failure were presented at the 2024 Fall Clinical Dermatology Conference.
Also Read: <a target="_blank" href="https://www.benzinga.com/general/biotech/24/10/41466839/justice-departments-trustee-program-alleges-johnson-johnsons-talc-litigation-bankruptcy-bid-is-ba" rel="noreferrer noopener">Justice Department&#8217;s Trustee Program Alleges Johnson &amp; Johnson&#8217;s Talc Litigation Bankruptcy Bid Is Bad-Faith Tactic To Avoid Liability</a>
A significantly greater proportion of patients who received Tremfya achieved the primary endpoint of an Investigator&#8217;s Global Assessment (IGA) score of cleared (0) or minimal disease compared to those who received placebo (74.2% versus 12.4%, respectively.
Significant clearance versus placebo at Week 16: scalp (75.0% versus 14.5%), face (87.8% versus 28.6%), intertriginous (86.5% versus 28.8%), and genital (78.0% versus 37.5%).
Complete clearance of each special site was consistently achieved in the majority of patients who received Tremfya versus placebo: scalp (60.3% versus 9.3%), face (75.7% versus 23.9%), intertriginous (76.6% versus 24.2%) and genital (72.7% versus 32.7%).
Statistically significant improvements were also achieved across all major secondary endpoints, including:
52.9% achieved a Psoriasis Area Severity Index (PASI) 90 response compared to 6.2% of participants who received a placebo (p&lt;0.001).
The average patient saw over 80% improvement from baseline for BSA and PASI compared to those who received placebo (80.6% versus 6.1% and 82.6% versus 13.7%, respectively; p&lt;0.001).
In the third quarter, Tremfya generated global sales of $1.01 billion, <a target="_blank" href="https://www.benzinga.com/general/biotech/24/10/41329767/johnson-johnsons-q3-earnings-revenue-and-eps-beat-on-strong-cancer-drug-sales-revises-annual-outl" rel="noreferrer noopener">13% year over year</a>.
Last month, the FDA approved Tremfya for adults with moderately to severely active ulcerative colitis, a chronic disease of the large intestine in which the colon<a target="_blank" href="https://www.benzinga.com/pressreleases/24/09/n40823500/tremfya-guselkumab-receives-u-s-fda-approval-for-adults-with-moderately-to-severely-active-ulcerat" rel="noreferrer noopener"> lining becomes inflamed</a>.
The European Medicines Agency is reviewing Tremfya for adults with moderately to severely active <a target="_blank" href="https://www.benzinga.com/pressreleases/24/10/n41269501/tremfya-guselkumab-demonstrates-impressive-results-across-biologic-na-ve-and-biologic-refractory-p" rel="noreferrer noopener">ulcerative colitis and Crohn&#8217;s disease</a>.&nbsp;
Price Action: JNJ stock is down 1.49% at $161.23 at the last check on Friday.
Read Next:
<ul>
<li><a href="https://www.benzinga.com/news/earnings/24/10/41550798/newell-brands-q3-earnings-margins-hit-highest-levels-since-2020-boosts-2024-eps-outlook-more" target="_blank" rel="noreferrer noopener">Newell Brands Q3 Earnings: Margins Hit Highest Levels Since 2020, Boosts 2024 EPS Outlook &amp; More</a></li>
</ul>
Photo via Wikimedia Commons

Johnson & Johnson's Blockbuster Drug Tremfya Clears Plaque Psoriasis With Lesions Covering Body's Smaller Areas

Launches Clinical Image Library To Aid Decision-Making For Diverse Skin Tones

Johnson & Johnson's SPECTREM Study Shows TREMFYA® (Guselkumab) Significantly Clears Low BSA Plaque Psoriasis In Special Sites; Achieves Primary And Secondary Endpoints In Phase 3b Trial

In today's rapidly evolving and fiercely competitive business landscape, it is crucial for investors and industry analysts to conduct comprehensive company evaluations. In this article, we will undertake an in-depth industry comparison, assessing Johnson &amp; Johnson (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/JNJ#NYSE">JNJ</a>) alongside its primary competitors in the Pharmaceuticals industry. By meticulously examining crucial financial indicators, market positioning, and growth potential, we aim to provide valuable insights to investors and shed light on company's performance within the industry.
<h3>Johnson &amp; Johnson Background</h3>
Johnson &amp; Johnson is the world's largest and most diverse healthcare firm. It has two divisions: pharmaceutical and medical devices. These now represent all of the company's sales following the divestment of the consumer business, Kenvue, in 2023. The drug division focuses on the following therapeutic areas: immunology, oncology, neurology, pulmonary, cardiology, and metabolic diseases. Geographically, just over half of total revenue is generated in the United States.
<table>
<thead>
<tr>
<th>Company</th>
<th>P/E</th>
<th>P/B</th>
<th>P/S</th>
<th>ROE</th>
<th>EBITDA (in billions)</th>
<th>Gross Profit (in billions)</th>
<th>Revenue Growth</th>
</tr>
</thead>
<tbody>
<tr>
<td>Johnson &amp; Johnson</td>
<td>27.41</td>
<td>5.58</td>
<td>4.60</td>
<td>6.62%</td>
<td>$7.8</td>
<td>$15.58</td>
<td>4.31%</td>
</tr>
<tr>
<td>Eli Lilly and Co</td>
<td>111.24</td>
<td>59.97</td>
<td>20.97</td>
<td>22.5%</td>
<td>$4.12</td>
<td>$9.13</td>
<td>35.98%</td>
</tr>
<tr>
<td>Novo Nordisk AS</td>
<td>39.75</td>
<td>31.57</td>
<td>13.85</td>
<td>18.97%</td>
<td>$35.74</td>
<td>$57.79</td>
<td>25.34%</td>
</tr>
<tr>
<td>Merck &amp; Co Inc</td>
<td>19.70</td>
<td>6.19</td>
<td>4.34</td>
<td>13.0%</td>
<td>$7.45</td>
<td>$12.37</td>
<td>7.16%</td>
</tr>
<tr>
<td>AstraZeneca PLC</td>
<td>37.35</td>
<td>6.04</td>
<td>4.89</td>
<td>5.01%</td>
<td>$4.12</td>
<td>$10.76</td>
<td>13.33%</td>
</tr>
<tr>
<td>Novartis AG</td>
<td>23.33</td>
<td>5.53</td>
<td>4.82</td>
<td>7.97%</td>
<td>$5.25</td>
<td>$9.7</td>
<td>9.6%</td>
</tr>
<tr>
<td>Sanofi SA</td>
<td>29.11</td>
<td>1.69</td>
<td>2.59</td>
<td>1.53%</td>
<td>$2.03</td>
<td>$7.97</td>
<td>6.53%</td>
</tr>
<tr>
<td>Zoetis Inc</td>
<td>37.06</td>
<td>17.24</td>
<td>9.73</td>
<td>12.45%</td>
<td>$0.97</td>
<td>$1.69</td>
<td>8.3%</td>
</tr>
<tr>
<td>GSK PLC</td>
<td>12.96</td>
<td>4.15</td>
<td>1.68</td>
<td>8.32%</td>
<td>$2.31</td>
<td>$5.76</td>
<td>9.84%</td>
</tr>
<tr>
<td>Takeda Pharmaceutical Co Ltd</td>
<td>44.43</td>
<td>0.85</td>
<td>1.50</td>
<td>1.26%</td>
<td>$388.51</td>
<td>$821.04</td>
<td>14.11%</td>
</tr>
<tr>
<td>Dr Reddy's Laboratories Ltd</td>
<td>19.70</td>
<td>3.71</td>
<td>3.79</td>
<td>4.84%</td>
<td>$21.72</td>
<td>$46.34</td>
<td>13.87%</td>
</tr>
<tr>
<td>Jazz Pharmaceuticals PLC</td>
<td>18.84</td>
<td>1.82</td>
<td>1.99</td>
<td>4.52%</td>
<td>$0.36</td>
<td>$0.91</td>
<td>6.95%</td>
</tr>
<tr>
<td>Corcept Therapeutics Inc</td>
<td>42.53</td>
<td>8.42</td>
<td>9.35</td>
<td>6.14%</td>
<td>$0.04</td>
<td>$0.16</td>
<td>39.15%</td>
</tr>
<tr>
<td>Organon &amp; Co</td>
<td>4.44</td>
<td>30.77</td>
<td>0.70</td>
<td>203.12%</td>
<td>$0.43</td>
<td>$0.94</td>
<td>-0.06%</td>
</tr>
<tr>
<td>Prestige Consumer Healthcare Inc</td>
<td>17.65</td>
<td>2.13</td>
<td>3.25</td>
<td>2.94%</td>
<td>$0.08</td>
<td>$0.15</td>
<td>-4.36%</td>
</tr>
<tr>
<td>Average</td>
<td>32.72</td>
<td>12.86</td>
<td>5.96</td>
<td>22.33%</td>
<td>$33.8</td>
<td>$70.34</td>
<td>13.27%</td>
</tr>
</tbody>
</table>
<style>
 table {
 width: 100%;
 border-collapse: collapse;
 font-family: Arial, sans-serif;
 font-size: 14px;
 }

 th, td {
 padding: 8px;
 text-align: left;
 }

 th {
 background-color: #293a5a;
 color: #fff;
 text-align: left;
 }

 tr:nth-child(even) {
 background-color: #f2f4f8;
 }

 tr:hover {
 background-color: #e1e4ea;
 }

 td:nth-child(3), td:nth-child(5) {
 text-align: left;
 }

 .dividend-amount {
 font-weight: bold;
 color: #0d6efd;
 }

 .dividend-frequency {
 font-size: 12px;
 color: #6c757d;
 }
 </style>Upon a comprehensive analysis of Johnson &amp; Johnson, the following trends can be discerned: 
<ul>
<li>
At 27.41, the stock's Price to Earnings ratio is 0.84x less than the industry average, suggesting favorable growth potential.
</li>
<li>
The current Price to Book ratio of 5.58, which is 0.43x the industry average, is substantially lower than the industry average, indicating potential undervaluation.
</li>
<li>
Based on its sales performance, the stock could be deemed undervalued with a Price to Sales ratio of 4.6, which is 0.77x the industry average.
</li>
<li>
The company has a lower Return on Equity (ROE) of 6.62%, which is 15.71% below the industry average. This indicates potential inefficiency in utilizing equity to generate profits, which could be attributed to various factors.
</li>
<li>
Compared to its industry, the company has lower Earnings Before Interest, Taxes, Depreciation, and Amortization (EBITDA) of $7.8 Billion, which is 0.23x below the industry average, potentially indicating lower profitability or financial challenges.
</li>
<li>
With lower gross profit of $15.58 Billion, which indicates 0.22x below the industry average, the company may experience lower revenue after accounting for production costs.
</li>
<li>
The company's revenue growth of 4.31% is significantly lower compared to the industry average of 13.27%. This indicates a potential fall in the company's sales performance.
</li>
</ul>
<h3>Debt To Equity Ratio</h3>
<img src="https://www.benzinga.com/files/images/story/2024/1729782055_0.png" alt="debt to equity" />
The debt-to-equity (D/E) ratio is an important measure to assess the financial structure and risk profile of a company.
Considering the debt-to-equity ratio in industry comparisons allows for a concise evaluation of a company's financial health and risk profile, aiding in informed decision-making.
By considering the Debt-to-Equity ratio, Johnson &amp; Johnson can be compared to its top 4 peers, leading to the following observations:
<ul>
<li>
Johnson &amp; Johnson demonstrates a stronger financial position compared to its top 4 peers in the sector.
</li>
<li>
With a lower debt-to-equity ratio of 0.58, the company relies less on debt financing and maintains a healthier balance between debt and equity, which can be viewed positively by investors.
</li>
</ul>
<h3>Key Takeaways</h3>
For Johnson &amp; Johnson in the Pharmaceuticals industry, the PE, PB, and PS ratios are all low compared to its peers, indicating potential undervaluation. However, the low ROE, EBITDA, gross profit, and revenue growth suggest underperformance relative to industry standards. This may signal a need for further investigation into the company's operational efficiency and growth strategies.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Comparative Study: Johnson &amp; Johnson And Industry Competitors In Pharmaceuticals Industry

<a href="https://www.jnj.com/media-center/press-releases/darzalex-daratumumab-sc-based-quadruplet-regimen-approved-by-the-european-commission-for-patients-with-newly-diagnosed-multiple-myeloma-who-are-transplant-eligible#:~:text=BEERSE%2C%20BELGIUM%20(23%20October%202024,and%20dexamethasone%20(daratumumab%2DVRd)">https://www.jnj.com/media-center/press-releases/darzalex-daratumumab-sc-based-quadruplet-regimen-approved-by-the-european-commission-for-patients-with-newly-diagnosed-multiple-myeloma-who-are-transplant-eligible#:~:text=BEERSE%2C%20BELGIUM%20(23%20October%202024,and%20dexamethasone%20(daratumumab%2DVRd)</a>
<h2>Phase 3 PERSEUS study of daratumumab subcutaneous (SC) formulation in combination with bortezomib, lenalidomide and dexamethasone induction and consolidation, followed by daratumumab SC and lenalidomide maintenance showed a 58 percent reduction in risk of disease progression or death1 New regimen reinforces daratumumab SC as a foundational element for optimising frontline treatment of patients with newly diagnosed multiple myeloma, and significantly delaying disease progression2</h2>

Global

DARZALEX-SC Based Quadruplet Regimen Approved By The European Commission For Patients With Newly Diagnosed Multiple Myeloma Who Are Transplant-Eligible

The U.S. Trustee Program, a unit of the Department of Justice (DOJ) overseeing bankruptcy cases, has filed a motion in federal bankruptcy court in Houston to dismiss a Chapter 11 filing by a subsidiary of Johnson &amp; Johnson (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/JNJ#NYSE">JNJ</a>).
The <a target="_blank" href="https://aboutblaw.com/bf1t" rel="noreferrer noopener">filing</a> aims to settle more than 60,000 talc-related lawsuits, marking J&amp;J's third attempt to pursue this strategy in as many years.
In September, Johnson &amp; Johnson reportedly increased its settlement offer by $1 billion, now totaling about $9 billion, to address claims that its talc baby powder&nbsp;<a target="_blank" href="https://www.benzinga.com/general/biotech/24/09/40738358/johnson-johnson-raises-talc-settlement-offer-to-9b-moves-closer-to-settlement-victory" rel="noreferrer noopener">caused gynecological cancer</a>.
The DOJ argues that Johnson &amp; Johnson's latest bankruptcy maneuver is a bad-faith attempt to shield itself from billions in personal injury claims without actually entering bankruptcy.
The company's approach involves creating a new subsidiary, transferring billions in liabilities but few assets to this entity, and then filing for bankruptcy on its behalf.
This move is seen as a way for Johnson &amp; Johnson to secure a third-party release that would discharge both itself and the subsidiary from liability—an action that was expressly prohibited in a recent Supreme Court ruling.
Johnson &amp; Johnson has used similar tactics in the past, both dismissed due to findings of bad faith.
Despite these setbacks, the company has filed this new case under a different entity and jurisdiction, which the DOJ believes is an attempt to sidestep previous rulings.
The trustee's motion claims that the debtor in question has no valid reason for bankruptcy protection and that the filing serves no legitimate restructuring purpose.
The ongoing litigation stems from numerous claims that Johnson &amp; Johnson's talc-based products, including baby powder, caused personal injuries.
Many lawsuits assert a link between talc exposure and ovarian cancer, while others allege that the products were contaminated with asbestos, leading to mesothelioma.
J&amp;J has consistently denied these allegations.
As of October 2021, around 36,000 ovarian cancer claims and 470 mesothelioma cases were tied to Johnson &amp; Johnson's talc products, with many cases consolidated in a multi-district litigation in New Jersey.
Price Action: JNJ stock closed 0.38% at $163.45 on Tuesday.
Read Next:
<ul>
<li><a href="https://www.benzinga.com/analyst-ratings/analyst-color/24/10/41463868/kimberly-clarks-growth-potential-underestimated-analyst-sees-attractive-entry-point" target="_blank" rel="noreferrer noopener">Kimberly-Clark's Growth Potential' Underestimated,' Analyst Sees Attractive Entry Point</a></li>
</ul>
Photo via Wikimedia Commons

Legal

Justice Department's Trustee Program Alleges Johnson & Johnson's Talc Litigation Bankruptcy Bid Is Bad-Faith Tactic To Avoid Liability

Johnson &amp; Johnson's (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/JNJ#NYSE">JNJ</a>) short percent of float has fallen 14.58% since its last report. The company recently reported that it has 19.74 million shares sold short, which is 0.82% of all regular shares that are available for trading. Based on its trading volume, it would take traders 3.21 days to cover their short positions on average.
<h3>Why Short Interest Matters</h3>
Short interest is the number of shares that have been sold short but have not yet been covered or closed out. <a href="https://www.benzinga.com/money/how-to-short-a-stock/">Short selling</a> is when a trader sells shares of a company they do not own, with the hope that the price will fall. Traders make money from short selling if the price of the stock falls and they lose if it rises.
Short interest is important to track because it can act as an indicator of market sentiment towards a particular stock. An increase in short interest can signal that investors have become more bearish, while a decrease in short interest can signal they have become more bullish.
See Also: <a href="https://www.benzinga.com/short-interest">List of the most shorted stocks</a>
<h3>Johnson &amp; Johnson Short Interest Graph (3 Months)</h3>
<img src="https://www.benzinga.com/files/images/story/2024/1729620922_0.png" alt="short_fig" />
As you can see from the chart above the percentage of shares that are sold short for Johnson &amp; Johnson has declined since its last report. This does not mean that the stock is going to rise in the near-term but traders should be aware that less shares are being shorted.
<h3>Comparing Johnson &amp; Johnson's Short Interest Against Its Peers</h3>
Peer comparison is a popular technique amongst analysts and investors for gauging how well a company is performing. A company's peer is another company that has similar characteristics to it, such as industry, size, age, and financial structure. You can find a company's peer group by reading its 10-K, proxy filing, or by doing your own similarity analysis.
According to <a href="https://pro.benzinga.com/">Benzinga Pro</a>, Johnson &amp; Johnson's peer group average for short interest as a percentage of float is 4.55%, which means the company has less short interest than most of its peers.
Did you know that increasing short interest can actually be bullish for a stock? <a href="https://www.benzinga.com/money/how-to-make-money-on-a-short-squeeze/">This post by Benzinga Money explains how you can profit from it.</a>
This article was generated by Benzinga's automated content engine and was reviewed by an editor.

Short Sellers

Short Ideas

Peering Into Johnson & Johnson's Recent Short Interest

Kenvue Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/KVUE#NYSE">KVUE</a>) shares are moving higher Monday following a report suggesting activist investor Starboard Value has acquired <a href="https://www.benzinga.com/markets/equities/24/10/41419988/tylenol-listerine-maker-kenvue-under-activist-spotlight-with-starboard-value-stake-overhaul-ahea">a stake in the company</a>. 
The Details: According to the <a href="https://www.wsj.com/business/deals/activist-starboard-value-takes-stake-in-tylenol-maker-kenvue-cc3175bb">Wall Street Journal</a>, Starboard has acquired a &#8220;sizable&#8221; stake in Kenvue and is pushing for changes to boost the consumer-products company&#8217;s share price. The activist investor asserts that Kenvue has &#8220;some of the best consumer brands,&#8221; yet its stock has lagged behind its competitors for over a year.
Kenvue&#8217;s iconic brands include Aveeno, BAND-AID Brand, Johnson&#8217;s, Listerine, Neutrogena and Tylenol. Kenvue shares are up just 7% year-to-date compared to more than 23% gains in the S&amp;P 500. Competitors Haleon (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/HLN#NYSE">HLN</a>) and Proctor and Gamble Company (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PG#NYSE">PG</a>) have climbed 21% and 16%, respectively, since the start of the year.
The exact size of Starboard's position in Kenvue was not shared. Starboard&#8217;s specific turnaround ideas were also not reported, but people familiar with the matter said Starboard CEO Jeff Smith is expected to discuss more about Starboard&#8217;s perspective on Kenvue at the 13D Monitor Active-Passive Investor Summit in New York on Tuesday. 
According to a separate <a href="https://www.msn.com/en-us/money/companies/activist-starboard-could-push-for-kenvue-to-sell-some-all-of-its-sbh-business-analyst/ar-AA1sEH3C?ocid=finance-verthp-feeds">report</a>, Starboard may try to push the company to sell its skin, healthcare and beauty division in whole or part.
In a note released Monday, JPMorgan analyst Andrea Teixeira said, &#8220;Given the SHB segment has been a key area of debate on the stock over the past year and a half, we would expect Starboard to detail changes it would like to see management make to this division — which we suspect could involve divesting some/all of the segment.&#8221;
Kenvue was spun out of Johnson &amp; Johnson (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/JNJ#NYSE">JNJ</a>) last year. The company currently has a market cap of more than $41 billion, according to data from <a href="http://pro.benzinga.com">Benzinga Pro</a>.
Related Link: <a href="https://www.benzinga.com/news/24/10/41417197/elon-musk-tesla-refute-inefficiency-concerns-with-wireless-charging-on-cybercab-there-is-no-meaningf">Elon Musk, Tesla Refute Inefficiency Concerns With Wireless Charging On Cybercab: &#8216;There Is No Meaningful Efficiency Difference…&#8217;</a>
KVUE Price Action: At the time of publication, Kenvue stock was up 5.96% at $23.02, according to data from <a href="https://www.benzinga.com/pro/">Benzinga Pro</a>.
Image: 3972315 from Pixabay.

Movers

KVUE

What's Going On With Kenvue Stock Monday?

Starboard Value, an activist investor, has reportedly acquired a substantial stake in Kenvue Inc (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/KVUE#NYSE">KVUE</a>), the company behind popular consumer products like Tylenol and Listerine.
What Happened: Starboard Value is pushing for changes at Kenvue, which was spun off from Johnson &amp; Johnson (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/JNJ#NYSE">JNJ</a>) last year and has a market value of over $40 billion, <a href="https://www.wsj.com/business/deals/activist-starboard-value-takes-stake-in-tylenol-maker-kenvue-cc3175bb?mod=breakingnews">reported</a> The Wall Street Journal, citing people familiar with the matter.
Despite having some of the best consumer brands in the industry, Kenvue&#8217;s stock has underperformed its peers and the broader market since its debut over a year ago.
The exact size of Starboard&#8217;s position in Kenvue and its specific ideas for the company are not known. Starboard&#8217;s founder and CEO, Jeff Smith, is expected to present the firm&#8217;s thesis on Kenvue at an activist investing conference in New York on Tuesday.
See Also: <a href="https://www.benzinga.com/markets/cryptocurrency/24/10/41372090/anthony-scaramucci-tells-what-percentage-of-his-wealth-is-tied-up-in-bitcoin-i-havent-sold?itm_source=parsely-api" target="_blank" rel="noreferrer noopener">Anthony Scaramucci Tells What Percentage Of His Wealth Is Tied Up In Bitcoin: &#8216;I Haven&#8217;t Sold Any. Thank God, Knock On Wood!&#8217;</a>
Kenvue&#8217;s other brands include Aveeno, Band-Aid, Zyrtec, Neosporin, and Neutrogena. The company, led by CEO Thibaut Mongon, recorded over $15 billion in net sales in 2023.
Kenvue and Starboard Value &nbsp;did not immediately respond to&nbsp;<a href="http://pro.benzinga.com/" target="_blank" rel="noreferrer noopener">Benzinga</a>'s request for comment.
Why It Matters: Kenvue&#8217;s stock price has remained relatively unchanged this year, in contrast to the S&amp;P 500 index&#8217;s 23% increase. The company&#8217;s biggest competitors include Haleon, the parent company of Advil, Procter &amp; Gamble, the owner of Pepto-Bismol, and Unilever, the maker of Axe deodorant.
Starboard&#8217;s recent investment in Kenvue follows its move to acquire a roughly $1 billion stake in Pfizer Inc., where it is seeking various changes to <a href="https://www.benzinga.com/markets/equities/24/10/41264265/former-pfizer-executives-ian-read-and-frank-damelio-support-albert-bourlas-leadership-amid-starb">improve the drugmaker&#8217;s performance</a>. This includes the appointment of former Pfizer executives Ian Read and Frank D&#8217;Amelio, who have pledged their support for current Pfizer CEO Albert Bourla.
Starboard is known for its active <a href="https://www.benzinga.com/markets/equities/24/07/39785537/tinder-parent-match-group-soars-nearly-9-in-after-hours-trading-as-activist-hedge-fund-starboard">involvement in various sectors</a>, including technology, where it has recently made efforts at companies like Salesforce, Autodesk, and Match Group.
Price Action: Kenvue Inc.&#8217;s stock closed at $21.72 on Friday, up 1.26% with a gain of $0.27. Year to date, the stock has risen by 0.70%, according to <a href="https://www.benzinga.com/pro/">data from Benzinga Pro</a>.
Read Next: 
<ul>
<li><a href="https://www.benzinga.com/markets/esg/24/10/41409688/this-small-cap-nuclear-stock-is-up-over-100-in-a-month-will-it-keep-generating-momentum?itm_source=parsely-api" target="_blank" rel="noreferrer noopener">This Small-Cap Nuclear Stock Is Up Over 100% In A Month: Will It Keep Generating Momentum?</a></li>
</ul>
Image Via Shutterstock 
This story was generated using <a href="https://www.benzinga.com/author/benzinga-neuro">Benzinga Neuro</a> and edited by <a href="https://www.benzinga.com/topic/Kaustubh-Bagalkote" target="_blank" rel="noreferrer noopener">Kaustubh Bagalkote</a>

Equities

Tylenol, Listerine Maker Kenvue Under Activist Spotlight With Starboard Value Stake — Overhaul Ahead For The Johnson & Johnson Spinoff?

In a year and a half, Eli Lilly (NYSE: <a class="ticker" href="https://www.benzinga.com/stock/lly#NYSE">LLY</a>) has roughly <a href="https://www.marketbeat.com/stocks/NYSE/LLY/chart/">doubled in value</a>. It is now the most valuable <a href="https://www.marketbeat.com/compare-stocks/pharmaceutical-stocks/">pharmaceutical company</a> in the world. It took that mantle from the long-held dominance by <a href="https://www.marketbeat.com/stocks/NYSE/JNJ/">Johnson and Johnson (NYSE: </a><a class="ticker" href="https://www.benzinga.com/stock/jnj#NYSE">JNJ</a>) back in May of 2023 and hasn&#39;t looked back since. However, much of that increase in value has come due to multiple expansions; the market is now paying more for every dollar of the company&#39;s earnings.
Revenues at Johnson and Johnson are still over double those of Eli Lilly over the last twelve months. Looking at net income, the relationship is similar. Compared to the beginning of May 2023, investors have now accepted paying around 2.8 times more for each dollar of earnings Eli Lilly has already generated. But, investors are paying around 40% less for each dollar of already generated J&amp;J earnings.
However, the stock market largely attributes value to a company based on its ability to generate earnings in the future. Based on Lilly&#39;s next twelve months forward P/E ratio, investors are paying about the same now for each dollar of future earnings as they were in May of 2023.
The gap between the backward-looking P/E and the forward-looking P/E suggests a belief that the company&#39;s earnings will rise strongly in the future. This would align its true earnings power with the stock price. In order to justify this, Lilly&#39;s earnings need to continue rising strongly in line with expectations. I will detail how the company plans to do this. I will also discuss potential catalysts that could help it exceed its high expectations.
<h3>Eli Lilly Is Growing Fast And Continues To Innovate</h3>
Much of the company&#39;s increase in value has come from intense excitement over its weight loss and diabetes drugs. Specifically, Zepbound and Mounjaro have experienced rapid sales growth. The former grew sales by 140% in just one quarter, based on the latest financial results. The older Mounjaro saw sales rise 72%. Although this growth is very impressive, the company needs to continue innovating to stay ahead of the game. Many smaller firms have seen the massive demand developing for these drugs over the years and are working on treatments to take a slice of the pie.
Lilly is pursuing an <a href="https://clinicaltrials.gov/study/NCT06440980?intr=Orforglipron&amp;rank=1">oral weight loss drug</a>. Other companies are doing this too, but Lilly&#39;s drug is comparatively further along than many others. The company could release Phase 3 Food and Drug Administration (FDA) results in mid to late 2025.
In contrast, Novo Nordisk (NYSE: <a class="ticker" href="https://www.benzinga.com/stock/nvo#NYSE">NVO</a>) recently released Phase 2 and Phase 1 results for oral weight loss treatments, which delays their potential timeline to market. This could allow the company to take on significant initial growth based on its already established reputation and first-mover advantage for patients who want this version of the drug.
The company also announced a <a href="https://www.reuters.com/business/healthcare-pharmaceuticals/lilly-announces-new-45-bln-manufacturing-site-indiana-2024-10-02/#:~:text=The%20facility%2C%20Lilly%20Medicine%20Foundry,to%20open%20in%20late%202027.">$4.5 billion investment</a>. It will build a new factory to ramp up production of unapproved drugs. This will allow it to hit the ground running if the drugs get approved.
<h3>Lilly Is Fighting Back Against Copycats And Expanding Its Market</h3>
Lilly also <a href="https://www.youtube.com/watch?v=6qtHRa-oxCA">recently began a program</a> where patients can directly purchase Zepbound for 50% less than the normal price from the company. However, patients can make these purchases with cash only; they cannot use insurance coverage. Zepbound is designed to treat obesity, not diabetes. So, many insurance plans do not cover it. This includes Medicare, the largest payer of healthcare services in the country.
This expands the market that the company can sell to and helps the firm fight back against unauthorized copycat distributors of the drug. It also provides some help to the company&#39;s inability to keep up with demand for its drug. It comes in a vial rather than an injectable pen. Not being able to make enough pens has been a key source of the undersupply.
On Oct. 3, the FDA removed Zepbound and Mounjaro <a href="https://www.fiercepharma.com/pharma/eli-lillys-shortage-glp-1-drugs-over-halting-competition-knock-offs">from its drug shortage list</a>, another positive sign. Additionally, Lily doesn&#39;t have all its eggs in the weight loss and diabetes market. These drugs made up 66% of revenue last quarter, but its two other largest treatment areas are also growing solidly. Immunology revenue increased by 30%, and oncology revenue increased by 20% last quarter.
<h3>Lilly Can Stay Top Dog</h3>
Overall, I am impressed by Lily&#39;s ability and willingness to find innovative solutions and stay ahead of the curve. I believe this bodes well for the future of the company and that the firm will continue to stay at the top of the heap in pharmaceuticals.
The article &quot;<a href="https://www.marketbeat.com/originals/why-eli-lilly-stock-is-soaringand-how-it-plans-to-stay-on-top/">Why Eli Lilly Stock Is Soaring&mdash;and How It Plans to Stay on Top</a>&quot; first appeared on MarketBeat.

Why Eli Lilly Stock Is Soaring—And How It Plans To Stay On Top

BofA Securities has upgraded Tyra Biosciences (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TYRA#NASDAQ">TYRA</a>), a clinical-stage biotechnology company focused on&nbsp;developing next-generation precision medicines.
The company&#8217;s <a target="_blank" href="https://tyra.bio/pipeline/" rel="noreferrer noopener">initial</a> focus is on improving small molecule drug discovery and development in targeted oncology and genetically defined conditions.
The company has a pipeline of four preclinical candidates. In July, Tyra Biosciences announced preclinical proof-of-concept results with TYRA-300 in hypochondroplasia (HCH), the most <a href="https://www.benzinga.com/pressreleases/24/07/n39605869/tyra-biosciences-announces-preclinical-proof-of-concept-results-with-tyra-300-in-hypochondroplasia" target="_blank" rel="noreferrer noopener">common form of dwarfism</a>.
TYRA-300 increased the length of the appendicular skeleton in the FGFR3 mutated mice: the femur by 3.70% compared to the vehicle, the tibia by 3.75%, the humerus by 3.22%, and the ulna by 5.03%.
TYRA-300 also increased the size of the foramen magnum by 5.88% (p&lt;0.05) in mice. TYRA-300 demonstrated binding against the FGFR3 N540K altered protein and isoform selectivity for FGFR3 over other isoforms.
BofA has upgraded Tyra Biosciences from Neutral to Buy with a price target <a target="_blank" href="https://www.benzinga.com/quote/TYRA/analyst-ratings" rel="noreferrer noopener">of $31, up from $22</a>, ahead of the upcoming presentation of the phase 1/2 SURF-301 of TYRA-300 for urothelial carcinoma/ solid tumors at the ENA Meeting next week.
The analyst suggests that while Johnson &amp; Johnson&#8216;s (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/JNJ#NYSE">JNJ</a>) erdafitinib may have established a high efficacy benchmark, its poor tolerability has significantly limited its use.
&#8220;To that end, we think the bar for success for &#8216;300 is safety vs. efficacy,&#8221; BofA analyst writes.
The updated model reflects greater potential uptake of an FGF3R-inhibitor with a differentiated safety profile while increasing the likelihood of success (LoS) risk adjustment to 35% from 15% prior in mUC.
The analyst projects 2030 adjusted sales for metastatic urothelial carcinoma to reach $175 million, up from a previous estimate of $35 million, compared to the consensus of $182 million.
The analyst highlights that Tyra Biosciences stock had a strong year (YTD +89% vs. +10% NBI)
Price Action: TYRA stock is up 3.77% at $26.96 at last check Friday.
Photo via Shutterstock
Read Next:
<ul>
<li><a href="https://www.benzinga.com/general/biotech/24/10/41407594/europe-drug-regulators-advising-panel-recommends-approval-of-novo-nordisks-australia-approved-hem" target="_blank" rel="noreferrer noopener">Europe Drug Regulator&#8217;s Advising Panel Recommends Approval Of Novo Nordisk&#8217;s Australia-Approved Hemophilia Drug</a>.</li>
</ul>

Analyst Color

Upgrades

TYRA

BofA Upgrades Tyra Biosciences As Investors Focus On Preclinical Data Amid High Benchmarks Set By Johnson & Johnson's Drug

Investors with a lot of money to spend have taken a bearish stance on Johnson &amp; Johnson (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/JNJ#NYSE">JNJ</a>).
And retail traders should know.
We noticed this today when the positions showed up on publicly available options history that we track here at Benzinga.
Whether these are institutions or just wealthy individuals, we don't know. But when something this big happens with JNJ, it often means somebody knows something is about to happen.
Today, Benzinga's options scanner spotted 8 options trades for Johnson &amp; Johnson.
This isn't normal.
The overall sentiment of these big-money traders is split between 37% bullish and 50%, bearish.
Out of all of the options we uncovered, there was 1 put, for a total amount of $104,000, and 7, calls, for a total amount of $338,554.
<h3>Predicted Price Range</h3>
Based on the trading activity, it appears that the significant investors are aiming for a price territory stretching from $160.0 to $180.0 for Johnson &amp; Johnson over the recent three months. 
<h3>Insights into Volume &amp; Open Interest</h3>
Assessing the volume and open interest is a strategic step in options trading. These metrics shed light on the liquidity and investor interest in Johnson &amp; Johnson's options at specified strike prices. The forthcoming data visualizes the fluctuation in volume and open interest for both calls and puts, linked to Johnson &amp; Johnson's substantial trades, within a strike price spectrum from $160.0 to $180.0 over the preceding 30 days.
<h3>Johnson &amp; Johnson Option Activity Analysis: Last 30 Days</h3>
<img src="https://www.benzinga.com/files/images/story/2024/1729269040_0.png" alt="Options Call Chart" />
<h3>Biggest Options Spotted:</h3>

<table>
<thead>
<tr>
<th>Symbol</th>
<th>PUT/CALL</th>
<th>Trade Type</th>
<th>Sentiment</th>
<th>Exp. Date</th>
<th>Ask</th>
<th>Bid</th>
<th>Price</th>
<th>Strike Price</th>
<th>Total Trade Price</th>
<th>Open Interest</th>
<th>Volume</th>
</tr>
</thead>
<tbody>
<tr>
<td>JNJ</td>
<td>PUT</td>
<td>TRADE</td>
<td>BEARISH</td>
<td>11/15/24</td>
<td>$2.63</td>
<td>$2.4</td>
<td>$2.6</td>
<td>$165.00</td>
<td>$104.0K</td>
<td>2.3K</td>
<td>481</td>
</tr>
<tr>
<td>JNJ</td>
<td>CALL</td>
<td>TRADE</td>
<td>BULLISH</td>
<td>11/15/24</td>
<td>$3.1</td>
<td>$2.3</td>
<td>$3.0</td>
<td>$165.00</td>
<td>$60.0K</td>
<td>7.9K</td>
<td>0</td>
</tr>
<tr>
<td>JNJ</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BEARISH</td>
<td>11/15/24</td>
<td>$3.05</td>
<td>$2.97</td>
<td>$2.97</td>
<td>$165.00</td>
<td>$59.4K</td>
<td>7.9K</td>
<td>1.0K</td>
</tr>
<tr>
<td>JNJ</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BEARISH</td>
<td>11/15/24</td>
<td>$3.2</td>
<td>$2.85</td>
<td>$2.93</td>
<td>$165.00</td>
<td>$58.5K</td>
<td>7.9K</td>
<td>404</td>
</tr>
<tr>
<td>JNJ</td>
<td>CALL</td>
<td>TRADE</td>
<td>BULLISH</td>
<td>11/15/24</td>
<td>$2.94</td>
<td>$2.9</td>
<td>$2.94</td>
<td>$165.00</td>
<td>$51.4K</td>
<td>7.9K</td>
<td>855</td>
</tr>
</tbody>
</table>

<h3>About Johnson &amp; Johnson</h3>
Johnson &amp; Johnson is the world's largest and most diverse healthcare firm. It has two divisions: pharmaceutical and medical devices. These now represent all of the company's sales following the divestment of the consumer business, Kenvue, in 2023. The drug division focuses on the following therapeutic areas: immunology, oncology, neurology, pulmonary, cardiology, and metabolic diseases. Geographically, just over half of total revenue is generated in the United States.
After a thorough review of the options trading surrounding Johnson &amp; Johnson, we move to examine the company in more detail. This includes an assessment of its current market status and performance.
<h3>Present Market Standing of Johnson &amp; Johnson</h3>
<ul>
<li>Currently trading with a volume of 1,877,656, the JNJ's price is up by 0.27%, now at $164.92. </li>
<li>RSI readings suggest the stock is currently may be approaching overbought.</li>
<li>Anticipated earnings release is in 95 days.</li>
</ul>
<h3>What The Experts Say On Johnson &amp; Johnson</h3>
Over the past month, 5 industry analysts have shared their insights on this stock, proposing an average target price of $201.0.
Unusual Options Activity Detected: Smart Money on the Move
Benzinga Edge's Unusual Options board spots potential market movers before they happen. See what positions big money is taking on your favorite stocks. <a href="https://www.benzinga.com/premium/ideas/benzinga-edge-checkout/?t=Be8be9arja3be22bz20&amp;utm_source=benzinga-insights">Click here for access</a>. 
&#x2A; Reflecting concerns, an analyst from Cantor Fitzgerald lowers its rating to Overweight with a new price target of $215. 
&#x2A; Reflecting concerns, an analyst from Cantor Fitzgerald lowers its rating to Overweight with a new price target of $215. 
&#x2A; Consistent in their evaluation, an analyst from Morgan Stanley keeps a Equal-Weight rating on Johnson &amp; Johnson with a target price of $175. 
&#x2A; An analyst from Cantor Fitzgerald downgraded its action to Overweight with a price target of $215. 
&#x2A; An analyst from Citigroup persists with their Buy rating on Johnson &amp; Johnson, maintaining a target price of $185. 
Options trading presents higher risks and potential rewards. Astute traders manage these risks by continually educating themselves, adapting their strategies, monitoring multiple indicators, and keeping a close eye on market movements. Stay informed about the latest Johnson &amp; Johnson options trades with real-time alerts from <a href="https://benzinga.grsm.io/register174">Benzinga Pro</a>.

Options

Johnson & Johnson Unusual Options Activity

Johnson &amp; Johnson&#39;s (NYSE: <a class="ticker" href="https://www.benzinga.com/stock/jnj#NYSE">JNJ</a>) stock price advance has been reinvigorated. The stock price rally stalled a few years ago due to the COVID-19 bubble bursting and the divestiture of Kenvue (NYSE: <a class="ticker" href="https://www.benzinga.com/stock/kvue#NYSE">KVUE</a>), but those days are behind, and business growth is still ahead. Today, Johnson &amp; Johnson is a buy because its value, yield, and growth outlook provide a vehicle capable of market-beating returns in 2025 and over the long term.&nbsp;
Regarding value, this healthcare stock is trading at 16x this year&#39;s earnings, less than half the historical average price multiple and well below the S&amp;P 500 average. Regarding returns, Johnson &amp; Johnson is a reliable dividend payer yielding more than 3%, more than double the broad market average, and at the high end of the historical range with a solid outlook for sustained distribution increases over the next few years.&nbsp;
<h2>Johnson &amp; Johnson Turns a Corner in Q3 2024</h2>
Johnson &amp; Johnson turned a corner in Q3 2024 with operational growth resulting in reported growth as comps to the COVID and pre-spinoff periods lapse. Reported growth is expected to continue in Q4 and next year, accelerating in 2025.&nbsp;
Regarding Q3, the company reported a 5.2% YoY increase in revenue driven by strengths in both operational regions and segments. Operational growth was more robust at 6.3% and 5.4% adjusted for COVID-19, with U.S. sales up by 7%, leading International&#39;s 4.6% growth and growth even near 6.35% in the Internal Medicine and Medical Technology segments. Internal Medicine and MedTech are driven by sustained strengths in existing treatments compounded by new approvals and product launches during the quarter.&nbsp;
The margin news is mixed but favorable to investors. Acquisitional costs, including acquired IPRD expenses, impacted GAAP and adjusted profits, but much less than expected. Because of this, GAAP and adjusted EPS, including IPRD costs, were contracted, but the impact of IPRD is worth 1900 basis points and is more than sufficient to offset the decline. Adjusted EPS is also 950 basis points better than expected.
The guidance is also mixed but favorable to shareholders. The company raised its guidance for revenue due to organic strength and the impact of the V-Wave acquisition but trimmed its target for earnings. The takeaway is that revenue is forecast above the consensus analysts&#39; target, the impact of the acquisition on earnings will diminish, and earnings are sufficient to sustain the capital return program, which is robust. The healthy dividend is compounded by share repurchases, which reduced the count by 4.7% in the quarter and 6.6% compared to last year.&nbsp;
<h2>Institutions Signal the Floor for Johnson &amp; Johnson Is $145</h2>
Institutional and analyst activity has been mixed over the last year, with intermittent selling periods and numerous negative revisions. However, institutional buying in 2024 coincides with price rebound in Q1 and Q3, which show solid support at the $145 level, which coincides with the low end of the analysts&#39;&nbsp;target range. Institutional activity could provide a tailwind in Q4 because activity in the first weeks remains bullish on balance.
Analyst activity is also shifting toward a more bullish bias. The activity in early October includes two reiterated Outperform ratings with price targets above the consensus reported by MarketBeat.com. The consensus of $175 implies a 5% upside and is rising in Q3 compared to last year and last quarter, with the upside range adding another $40 or nearly 25%.&nbsp;
The technical outlook is bullish. The market for JNJ stock is range-bound within a multiyear range but moving upward within it. The latest activity shows the market in rally mode and consolidating beneath a critical uptrend line, setting up to move higher over the coming weeks. Assuming the market follows through on the signal, JNJ could hit the top of the range near $180 by early 2025.&nbsp;
<img alt="Johnson &amp; Johnson JNJ stock chart" class="aligncenter" src="https://www.marketbeat.com/logos/articles/med_20241015124542_chart-jnj-10152024.png" style="height:446px; width:917px" />
The article &quot;<a href="https://www.marketbeat.com/originals/johnson-and-johnson-stock-setting-the-stage-for-2025-highs/">Johnson &amp; Johnson Stock: Setting the Stage for 2025 Highs</a>&quot; first appeared on MarketBeat.

Earnings

Guidance

Technicals

Johnson & Johnson Stock: Setting the Stage for 2025 Highs

Citigroup analyst Joanne Wuensch maintains Johnson &amp; Johnson (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/JNJ#NYSE">JNJ</a>) with a Buy and raises the price target from $180 to $185.

Citigroup Maintains Buy on Johnson & Johnson, Raises Price Target to $185

On Tuesday,&nbsp;Johnson &amp; Johnson (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/JNJ#NYSE">JNJ</a>)&nbsp;reported a third-quarter adjusted EPS of $2.42, down 9.0% year-over-year, beating the&nbsp;<a target="_blank" href="https://www.benzinga.com/calendars/earnings" rel="noreferrer noopener">consensus of $2.21</a>. The pharmaceutical giant reported sales of $22.47 billion, up 5.2% year over year and beating the consensus&nbsp;<a target="_blank" href="https://www.benzinga.com/general/biotech/24/10/41329767/johnson-johnsons-q3-earnings-revenue-and-eps-beat-on-strong-cancer-drug-sales-revises-annual-outl" rel="noreferrer noopener">of $22.16 billion</a>.
Johnson &amp; Johnson updated the full-year 2024 adjusted operational EPS guidance to reflect improved performance and the acquisition of V-Wave; the costs associated with the acquisition more than&nbsp;<a target="_blank" href="https://www.benzinga.com/general/biotech/24/08/40464864/johnson-johnson-strikes-1-7b-deal-to-acquire-heart-tech-innovator-v-wave" rel="noreferrer noopener">offset the improvement</a>.
BofA Securities reiterates a Neutral rating and a <a target="_blank" href="https://www.benzinga.com/quote/JNJ/analyst-ratings" rel="noreferrer noopener">price target of $170</a>. The analyst projects the Oncology franchise will maintain strong performance next year, with Darzalex and Carvykti expanding their market share globally in first—and second-line+ treatments for multiple myeloma.
Also Read: <a target="_blank" href="https://www.benzinga.com/general/biotech/24/10/41189182/johnson-johnson-ends-phase-2-study-for-dengue-antiviral-amid-r-d-reprioritization" rel="noreferrer noopener">Johnson &amp; Johnson Ends Phase 2 Study For Dengue Antiviral Amid R&amp;D Reprioritization</a>.
The analyst also anticipates a boost in Rybrevant sales for EGFR+ lung cancer following the approval and launch of its subcutaneous formulation in the first half of 2025.
Additionally, Tremfya is expected to post over 20% year-over-year growth, driven by ongoing launches for inflammatory bowel disease.
In contrast, Stelara could rapidly decline by around 25% as biosimilars enter the U.S. market in January 2025.
Meanwhile, the MedTech segment will likely encounter challenges due to volume-based procurement pressures.
The outcome of the talc litigation remains uncertain. U.S. courts will decide whether Johnson &amp; Johnson can use bankruptcy proceedings to resolve current and future claims.
Needham reports that while Johnson &amp; Johnson saw a slight slowdown in organic MedTech growth in Q3 2024 compared to Q2, with sales falling about 2% below consensus, the analyst attributes this to specific company factors.
These include a higher exposure to the Chinese market, the Orthopedics Transformation program, and competitive pressures.
Management also highlighted potential headwinds in Q4 2024 due to recent hurricanes but expressed greater concern over the shortage of IV solutions than the direct impact of the storms on procedures.
Overall, the analyst views Johnson &amp; Johnson&#8217;s performance as neutral for most of the med tech sector.
Price Action: JNJ stock is up 0.15% at $164.34 at the last check Wednesday.
Read Next:
<ul>
<li><a href="https://www.benzinga.com/general/biotech/24/10/41360197/gsk-seeks-fda-approval-for-oral-antibiotic-for-urinary-tract-infections-probably-first-in-new-cla" target="_blank" rel="noreferrer noopener">GSK Seeks FDA Approval For Oral Antibiotic For Urinary Tract Infections, Probably First In New Class In Over 20 Years</a></li>
</ul>
Photo by Tada Images via Shutterstock

Johnson & Johnson's MedTech Challenges Loom Amid Chinese Market Pressures And Orthopedics Overhaul, Analysts Say

Goldman Sachs downgraded Option Care Health (OPCH) to Neutral from Buy with a $27 price target. The firm had previously held the view that Option C...

Option Care Health downgraded to Neutral at Goldman on Stelara headwinds

The most talked about and market moving research calls around Wall Street are now in one place. Here are today's research calls that investors need...

Roblox, Peloton upgraded: Wall Street's top analyst calls

New study reveals another benefit in using Novo Nordisk's Wegovy in obesity

Johnson & Johnson Darzalex shows efficacy in early-stage multiple myeloma

With the rise of chronic diseases, technological advances and innovative drug pipelines are driving significant growth in the healthcare industry. Hence, investors may find long-term stability and exciting opportunities by adding stocks, Johnson & Johnson (JNJ), Pfizer (PFE), and Cigna Group (CI), to their portfolios. Read more… With a growing population and rising rates of chronic conditions, the demand for better healthcare solutions has never been greater. Thus, scooping shares of fundamentally sound healthcare stocks, Johnson &amp; Johnson (<a href="https://stocknews.com/stock/JNJ/">JNJ</a>), Pfizer Inc. (<a href="https://stocknews.com/stock/PFE/">PFE</a>), and The Cigna Group (<a href="https://stocknews.com/stock/CI/">CI</a>), could provide significant gains and long-term stability.
Chronic diseases are becoming more prevalent worldwide, leading to a surge in demand for innovative treatments. As conditions like heart disease, diabetes, and respiratory issues rise, healthcare providers and pharmaceutical companies must meet the increasing need for effective and accessible solutions to manage these ailments.
That said, Artificial intelligence (AI) and machine learning are <a href="https://health.clevelandclinic.org/ai-in-healthcare">reshaping the healthcare landscape</a>. By improving task management, patient services, and complex measurements, AI is streamlining operations and accelerating the healthcare industry's growth, making it more efficient and patient centric.
Moreover, the industry continues to demonstrate its potential, as seen with the U.S. Food and Drug Administration's <a href="https://www.fda.gov/drugs/novel-drug-approvals-fda/novel-drug-approvals-2024">approval of 38 new drugs</a> for chronic conditions this year. With global pharmaceutical revenue expected to <a href="https://www.statista.com/outlook/hmo/pharmaceuticals/worldwide">hit $1.45 trillion by 2029</a>, growing at a steady CAGR of 4.7%, the future of healthcare looks promising.
With these conductive trends in mind, let us dive deep into the fundamentals of three healthcare stocks, starting with #3.
Stock #3: Johnson &amp; Johnson (<a href="https://stocknews.com/stock/JNJ/">JNJ</a>)
JNJ researches, develops, manufactures, and sells a variety of healthcare products. Its offerings address conditions such as immunology, infectious diseases, neuroscience, oncology, and pulmonary hypertension. The company operates through two segments: Innovative Medicine and MedTech.
On October 10, JNJ <a href="https://s203.q4cdn.com/636242992/files/doc_news/2024/Oct/10/final-volt-press-release-us_dps_trex_391290.pdf">announced the launch</a> of the first phase of VOLT&#x2122; Variable AngleOptimized Locking Technology Plating System, an innovative system for fracture management solutions. This positions JNJ to strengthen its presence in the orthopedic trauma market, driving market share growth and stable opportunities.
On October 9, JNJ <a href="https://www.investor.jnj.com/news/news-details/2024/Johnson--Johnson-Completes-Acquisition-of-V-Wave/default.aspx">announced the completion of acquisition</a> of V-Wave Ltd., a privately held company focused on developing innovative treatment options for patients with heart failure. The acquisition could allow JNJ to broaden its product offerings and capitalize on emerging opportunities in the growing field of heart disease management.
For the fiscal 2024 third quarter that ended on September 29, JNJ's sales to customers increased 5.2% year-over-year to $22.47 billion. Its <a href="https://www.investopedia.com/terms/g/grossprofit.asp">gross profit</a> also grew 5.2% from the year-ago value to $15.51 billion. Additionally, the company's net earnings and net earnings per share from continuing operations came in at $2.69 billion and $1.11, respectively.
Analysts expect JNJ's revenue for the fiscal year ending December 2024 to increase 4.3% year-over-year to $88.79 billion. Its EPS for the ongoing fiscal year is expected to grow marginally from the previous year to $9.96. Plus, the company topped the consensus EPS estimates in all four trailing quarters.
JNJ's stock has increased by 6.1% over the past six months, closing the last trading session at $158.35. The company maintains a 24-month beta of 0.25, reflecting its relatively low market volatility.
JNJ's <a href="https://stocknews.com/powr-ratings/">POWR Ratings</a> mirror its strong fundamentals. The stock has an overall rating of A, which translates to a Strong Buy in our proprietary rating system. The POWR Ratings assess stocks by 118 different factors, each with its own weighting.
JNJ has a B grade for Value, Stability, and Quality. It is ranked #14 out of 160 stocks in the <a href="https://stocknews.com/category/pharmaceuticals/">Medical – Pharmaceuticals</a> industry.
To check the stock's ratings for Growth, Sentiment, and Momentum, <a href="https://stocknews.com/stock/JNJ/">click here</a>.
Stock #2: Pfizer Inc. (<a href="https://stocknews.com/stock/PFE/">PFE</a>)
PFE is a global, research-driven biopharmaceutical company that discovers, develops, manufactures, markets, sells, and distributes biopharmaceutical products. It provides medicines and vaccines in therapeutic areas such as cardiovascular metabolic, migraine, and women's health.
On October 22, PFE <a href="https://investors.pfizer.com/Investors/News/news-details/2024/U.S.-FDA-Approves-Pfizers-RSV-Vaccine-ABRYSVO-for-Adults-Aged-18-to-59-at-Increased-Risk-for-Disease/default.aspx">announced the U.S. Food and Drug Administration (FDA) approval</a> of ABRYSVO, bivalent RSV prefusion F (RSVpreF) vaccine, for the prevention of lower respiratory tract disease (LRTD) caused by RSV in individuals 18 through 59 years of age who are at increased risk for LRTD caused by RSV.
With this approval, the company could expand its footprint in infectious disease prevention, opening doors to new opportunities and solidifying its reputation as a leader in innovative healthcare solutions.
On October 11, PFE <a href="https://investors.pfizer.com/Investors/News/news-details/2024/U.S.-FDA-Approves-Pfizers-HYMPAVZI-marstacimab-hncq-for-the-Treatment-of-Adults-and-Adolescents-with-Hemophilia-A-or-B-Without-Inhibitors/default.aspx">announced the FDA approval</a> for HYMPAVZI, a drug for routine prophylaxis to prevent or reduce the frequency of bleeding episodes in adults and pediatric patients 12 years of age and older with hemophilia A without factor VIII inhibitors or hemophilia B without factor IX inhibitors.
The approval strengthens PFE's position in the rare disease market. As the company broadens its therapeutic offerings, HYMPAVZI provides a vital tool for managing hemophilia, paving the way for increased growth in this specialized area of healthcare.
For the fiscal third quarter that ended on September 29, 2024, PFE's total revenues increased 31.2% year-over-year to $17.70 billion. The adjusted net income and adjusted earnings per common share attributable to PFE common shareholders stood at $6.05 billion and $1.06, compared to a net loss and loss per share of $968 million and $0.17 in the prior year's quarter, respectively.
Street expects PFE's revenue and EPS for the fiscal fourth quarter (ending December 2024) to increase 21.9% and 358% year-over-year to $17.36 billion and $0.46, respectively. Moreover, the company topped the consensus EPS estimates in all four trailing quarters.
PFE's stock has risen 5.3% over the last nine months, with the latest close at $27.99. The company's 24-month beta stands at 0.23, highlighting its lessened exposure to market fluctuations.
PFE's solid prospects are projected in its POWR Ratings. The stock has an overall rating of B, which translates to a Buy in our proprietary rating system.
PFE has an A grade for Growth and a B for Value. It is ranked #37 within the Medical – Pharmaceuticals industry.
<a href="https://stocknews.com/stock/PFE/">Click here</a> to access PFE's ratings for Quality, Momentum, Stability, and Sentiment.
Stock #1: The Cigna Group (<a href="https://stocknews.com/stock/CI/">CI</a>)
CI offers insurance and related services. Its Evernorth segment provides coordinated and point-solution health services. Meanwhile, the Cigna Healthcare segment delivers medical, pharmacy, behavioral health, dental, and other products, including Medicare plans and international health coverage for individuals and employees.
On January 31, CI <a href="https://newsroom.thecignagroup.com/2024-01-31-The-Cigna-Group-to-Sell-Medicare-Businesses-and-CareAllies-to-Health-Care-Service-Corporation-HCSC">announced a definitive agreement</a> for Health Care Service Corporation (HCSC) to acquire its Medicare Advantage, Cigna Supplemental Benefits, Medicare Part D, and CareAllies businesses for an approximate transaction value of $3.7 billion. This would enable CI to unlock substantial value for stakeholders by freeing up resources to accelerate investment in its services platform.
For the fiscal third quarter that ended on September 30, 2024, CI's adjusted revenues increased 29.8% year-over-year to $63.70 billion. Its adjusted income from operations rose 5% from the year-ago value to $2.11 billion. Moreover, the company's adjusted income from operations per share rose 10.9% from the prior year's quarter to $7.51.
The consensus revenue estimate of $62.91 billion for the fiscal fourth quarter (ending December 2024) reflects a year-over-year rise of 23%. Its EPS for the same period is expected to increase 15.4% from the prior year's period to $7.84. Also, the company topped the consensus revenue and EPS estimates in all four trailing quarters, which is impressive.
CI's shares have gained 6.3% year-to-date, closing the last trading session at $318.39. The stock holds a 24-month beta of 0.13, indicating its low volatility in comparison to broader market movements.
CI's POWR Ratings reflect its sound outlook. The stock has an overall rating of B, which translates to a Buy in our proprietary rating system.
CI has a B grade for Growth, Value, and Sentiment. It has topped the 10-stock A-rated <a href="https://stocknews.com/category/health-insurance/">Medical - Health Insurance</a> industry.
To check CI's Quality, Momentum, and Stability ratings, <a href="https://stocknews.com/stock/CI/">click here</a>.
What To Do Next?
Get your hands on this special report with 3 low priced companies with tremendous upside potential even in today's volatile markets:
<a href="https://report.stocknews.com/free-report/3stocks/?formplacement=artbotad_3s">3 Stocks to DOUBLE This Year &gt;</a>
<hr />
JNJ shares were unchanged in premarket trading Wednesday. Year-to-date, JNJ has gained 3.40%, versus a 22.48% rise in the benchmark S&amp;P 500 index during the same period.
<hr><div style="clear:both;"></div> <h2>About the Author: Aanchal Sugandh</h2> <img src='https:/wp-content/uploads/2022/12/Aanchal-Sugandh_Headshot.jpg' style="float:left; padding:5px;width:125px;">Aanchal's passion for financial markets drives her work as an investment analyst and journalist. She earned her bachelor's degree in finance and is pursuing the CFA program.

She is proficient at assessing the long-term prospects of stocks with her fundamental analysis skills. Her goal is to help investors build portfolios with sustainable returns.<a href="https://stocknews.com/authors/?author=aanchal-sugandh">More...</a>The post <a href=https://stocknews.com/news/jnj-pfe-ci-3-healthcare-stocks-for-long-term-stability-and-growth/>3 Healthcare Stocks for Long-Term Stability and Growth</a> appeared first on <a href=https://stocknews.com/>StockNews.com</a>

3 Healthcare Stocks for Long-Term Stability and Growth

BeiGene: TEVIMBRA European Push Continues With Positive CHMP Opinion

QLV: Better Low-Volume ETF Than Quality ETF

SA Asks: How will the U.S. election results impact healthcare stocks?

Amid current economic uncertainties and market volatility, investing in defensive stocks appears as an ideal strategy for portfolio protection. Thus, quality defensive stocks Johnson & Johnson (JNJ), Pfizer (PFE), and Genie Energy (GNE) could be ideal portfolio additions as market volatility rises. Continue reading... Defensive stocks are stocks of companies that deliver products and services of essential or <a href="https://www.investopedia.com/terms/d/defensivestock.asp">necessary nature like healthcare, medicines</a>, basic utilities, consumer goods, etc. The demand for such companies is the same through various business cycles, and therefore, they offer stable income and growth prospects to investors, making them ideal investment choices during market uncertainties.
Given this backdrop, it could be wise to invest in quality defensive stocks Johnson &amp; Johnson (<a href="https://stocknews.com/stock/JNJ/">JNJ</a>), Pfizer Inc. (<a href="https://stocknews.com/stock/PFE/">PFE</a>), and Genie Energy Ltd. (<a href="https://stocknews.com/stock/GNE/">GNE</a>) for stability amid market volatility.
The U.S. economy has been showing mixed growth this year with each quarter. The economy grew at a 1.3% annualized rate in the first quarter, indicating slow expansion, whereas during the second quarter, the rate rose to 3.0%, fueled by strong household income growth and consumer spending.
Last week, the Bureau of Economic Analysis (BEA) <a href="https://www.commerce.gov/news/blog/2024/11/commerce-data-show-strong-economic-gains-due-americans-making-and-spending-more#:~:text=The%20U.S.%20Commerce%20Department's%20Bureau,Americans%20making%20and%20spending%20more.">reported GDP growth of 2.8%</a> at an annual rate in the third quarter of 2024, lower than the economists' estimate of 3.0%. The development during the quarter was driven by increasing consumer spending, which increased by 3.7%, the highest since the first quarter of 2023.
This market volatility has caused investors to seek defensive stocks that remain stable during market downturns and offer stable income through dividends and long-term growth opportunities.
Demand for healthcare amenities remains constant, as the need for medical treatments remains the same regardless of economic conditions. Hence, the sector offers investors stability and protection during market downturns. Likewise, basic utilities such as goods and services like water, gas, and electricity cannot be avoided or subset, given their necessity for survival.
Therefore, investing in defensive stocks amidst economic uncertainties is ideal due to constant consumer demand, stable income, and portfolio protection. Given these factors, let's delve deeper into the fundamentals of the top defensive stocks: JNJ, PFE, and GNE.
Johnson &amp; Johnson (<a href="https://stocknews.com/stock/JNJ/">JNJ</a>)
JNJ researches, develops, manufactures, and sells various products in the healthcare field internationally. The company operates in the Innovative Medicine and MedTech segments. It offers products for various therapeutic areas, like immunology, including rheumatoid arthritis, psoriatic arthritis, inflammatory bowel disease, and psoriasis.
On October 28, JNJ announced results from the Phase 3 GRAVITI study of TREMFYA&#xAE; (guselkumab), the first and only IL-23 inhibitor. TREMFYA showed robust subcutaneous induction and maintenance therapy results, demonstrating significant clinical remission and endoscopic response at 48 weeks in adults with moderately to severely active CD.
Upon FDA approval, TREMFYA&#xAE; could become the first IL-23 treatment to offer a subcutaneous and intravenous (IV) induction regimen for patients with Crohn's disease (CD).
On October 9, JNJ completed the acquisition of V-Wave Ltd., a privately held company focused on developing innovative treatment options for patients with heart failure. The acquisitions added V-Wave's novel and minimally invasive Ventura&#xAE; interatrial shunt to the Johnson &amp; Johnson MedTech portfolio and will also strengthen its position in the cardiovascular disease segment.
During the nine months that ended September 30, 2024, JNJ's reported sales increased 4% year-over-year to $66.30 billion. Its <a href="https://www.investopedia.com/terms/g/grossprofit.asp#:~:text=Gross%20profit%2C%20or%20gross%20income,fluctuate%20compared%20to%20production%20output.">gross profit</a> rose 4.4% year-over-year to $45.96 billion. The company's net earnings from continuing operations of $10.64 billion and $4.83 indicate increases of 15.7% and 24.1% from the prior year's period, respectively.
Analysts expect JNJ's EPS for the fourth quarter (ending December 2024) to increase 0.9% year-over-year to $2.31, and its revenue is estimated to increase 5% year-over-year to $22.47 billion for the same quarter. Moreover, the company surpassed the consensus EPS estimates in each of the trailing four quarters.
JNJ's stock has soared 9.7% over the past month and 2.5% over the past six months to close the last trading session at $160.62.
JNJ's growth prospects are reflected in its <a href="https://stocknews.com/powr-ratings/">POWR Ratings</a>. The stock has an overall rating of A, equating to a Strong Buy in our proprietary rating system. The POWR Ratings are calculated by considering 118 different factors, each weighted to an optimal degree.
The stock has a B grade for Stability, Quality, and Value. Within the <a href="https://stocknews.com/category/pharmaceuticals/">Medical - Pharmaceuticals</a> industry, JNJ is ranked #14 out of 160 stocks.
<a href="https://stocknews.com/stock/JNJ/">Click here</a> to access additional ratings of JNJ for Growth, Sentiment, and Momentum.
Pfizer Inc. (<a href="https://stocknews.com/stock/PFE/">PFE</a>)
PFE discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products worldwide. The company offers medicines and vaccines in various therapeutic areas like cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and Premarin family brands.
On October 22, PFE received the U.S. FDA approval for its ABRYSVO&#xAE; (Respiratory Syncytial Virus Vaccine), a bivalent RSV prefusion F (RSVpreF) vaccine to prevent lower respiratory tract disease (LRTD) caused by RSV in individuals between 18 and 59 years of age. ABRYSVO offers the broadest indication of the RSV vaccine in adults.
The approval was based on data from the pivotal Phase 3 trial. ABRYSVO is the first and only respiratory syncytial virus vaccine indicated for adults younger than 50. Also, the indication has now been expanded to benefit older adults and pregnant women.
Also, in the same month, PFE received FDA approval for HYMPAVZI&#x2122; (marstacimab-hncq) for routine prophylaxis to prevent or reduce the frequency of bleeding episodes in adults and pediatric patients 12 years of age and older with hemophilia A. The approval marked a significant advancement for people living with hemophilia A or B without inhibitors for bleed prevention.
During the third quarter that ended September 29, 2024, PFE's total revenues rose 31.2% from the prior-year quarter to $17.70 billion, of which its product revenues grew 33.1% year-over-year to $15.42 billion. The company's adjusted net income and EPS came in at $6.05 billion and $1.06 for the quarter, respectively.
The company had raised its full-year 2024 revenue guidance to a range of $61 billion to $64 billion from the prior range of $59.50 to $62.50 billion. PFE also raised its adjusted EPS guidance to a range of $2.75 to $2.95.
The consensus EPS estimate of $0.46 for the fiscal fourth quarter (ending December 2024) represents a 358% improvement year-over-year. The consensus revenue estimate of $17.36 billion for the ongoing quarter represents a 21.9% increase from last year. The company has an impressive surprise history; it surpassed the consensus EPS estimates in all of the trailing four quarters.
PFE's stock has surged 0.7% over the past six months and 3.9% over the past nine months to close the last trading session at $27.99.
PFE's bright outlook is reflected in its POWR Ratings. It has an overall rating of B, which translates to a Buy in our proprietary rating system.
The stock has an A grade for Growth. It also has a B grade for Value. PFE is ranked #37 among the 160 stocks in the Medical - Pharmaceuticals industry.
<a href="https://stocknews.com/stock/PFE/">Click here</a> to access PFE's other ratings for Quality, Momentum, Stability, and Sentiment.
Genie Energy Ltd. (<a href="https://stocknews.com/stock/GNE/">GNE</a>)
GNE is engaged in the supply of electricity and natural gas to residential and small business customers internationally. The company operates in two segments, GRE and Genie Renewables. It develops, constructs, and operates solar energy projects for commercial and industrial customers.
On March 21, GNE's subsidiary, Sunlight Energy Investments, a retail energy and renewable energy solutions provider, purchased a late-stage solar development project in Hamilton, Indiana, from the project developer. The Hamilton project acquisition fits perfectly with the company's growing portfolio of solar projects, which offers long-term, stable cash flows.
GNE reported total revenue of $90.70 million for the second quarter that ended June 30, 2024, and its income from operations was $10.56 million for the same period. The company's net income attributable to Genie common stockholders and EPS came in at $9.61 million and $0.36 for the quarter, respectively.
Shares of GNE have declined marginally over the past six months to close the last trading session at $15.67.
GNE's POWR Ratings reflect its robust outlook. GNE has an overall B rating, equating to a Buy in our proprietary rating system.
The stock has a B grade for Quality, Sentiment, Momentum, and Value. It is ranked #2 among the 59 stocks in the <a href="https://stocknews.com/category/utilities-domestic/">Utilities - Domestic</a> industry.
<a href="https://stocknews.com/stock/GNE/">Click here</a> to access additional GNE ratings for Stability and Growth.Top of Form
What To Do Next?
Get your hands on this special report with 3 low priced companies with tremendous upside potential even in today's volatile markets:
<a href="https://report.stocknews.com/free-report/3stocks/?formplacement=artbotad_3s">3 Stocks to DOUBLE This Year &gt;</a>

<hr />
JNJ shares were trading at $158.20 per share on Wednesday afternoon, down $0.15 (-0.09%). Year-to-date, JNJ has gained 3.30%, versus a 25.58% rise in the benchmark S&amp;P 500 index during the same period.
<hr><div style="clear:both;"></div> <h2>About the Author: Rjkumari Saxena</h2> <img src='https:/wp-content/uploads/2024/04/Rajkumari-Saxena_Image-1.jpeg' style="float:left; padding:5px;width:125px;">Rajkumari started her career as a writer but gradually shifted her focus to financial journalism, leveraging her educational background in Commerce. Fascinated by the interplay of business and economic shifts in equities, she aspires to evolve as an analyst. With a knack for simplifying complex financial concepts, her mission is to empower investors with insights that lead to profitable decisions.<a href="https://stocknews.com/authors/?author=rajkumari-saxena">More...</a>The post <a href=https://stocknews.com/news/jnj-pfe-gne-3-defensive-stocks-to-buy-as-market-volatility-rises/>3 Defensive Stocks to Buy as Market Volatility Rises</a> appeared first on <a href=https://stocknews.com/>StockNews.com</a>

3 Defensive Stocks to Buy as Market Volatility Rises

From Growth To Value: Building A Portfolio With Brett Ashcroft Green

AAPL

ABBV

AMGN

AMZN

BABA

BABAF

BAIDF

BEIGF

BGNE

BIDU

CASY

CHTR

COST

FDLO

FHLC

FQAL

FVRR

ITOCF

ITOCY

JQUA

KWEB

LGLV

MARUF

MARUY

MITSF

MITSY

MSBHF

MSFT

MTSUY

NCLH

NKTR

NVDA

ONEV

OPCH

PCRFF

PCRHY

PTON

QQMG

QUAL

RBLX

SBUX

SCHD

SPHQ

SPLV

SPTM

SSUMF

SSUMY

TEVA

TOYOF

USMV

Screenshot 2024-09-30 at 9.13.36 PM

TNXP

VRTX

The Rush For Non-Addictive Painkillers To Counter The Opioid Crisis Puts Two Companies Closer To FDA Decisions

Screenshot 2024-04-30 at 5.36.02 PM

Cardio Diagnostics Holdings Inc. - Common stock

CDIO

MRNA

3 Trends In Healthcare Guided By AI And The Companies Behind The Innovation

Screenshot 2024-03-13 at 5.45.52 PM

FDXTF

SHTDY

Nanotechnology&#39;s Promising Role In Fighting Infectious Diseases: Protecting Surfaces With FendX&#39;s Nanotechnology

Press Releases

TREMFYA® (guselkumab) demonstrates impressive results across biologic-naïve and biologic-refractory patients in Crohn's disease and ulcerative colitis

Johnson & Johnson to Participate in the Stifel 2024 Healthcare Conference

Johnson & Johnson Reports Q3 2024 Results

Johnson & Johnson Announces Quarterly Dividend for Fourth Quarter 2024

Nipocalimab demonstrates sustained disease control in adolescents living with generalized myasthenia gravis in Phase 2/3 study

Connecticut Jury Delivers $15 Million Asbestos Verdict Against Johnson & Johnson

Johnson & Johnson highlights innovative neuropsychiatry portfolio and pipeline at Psych Congress

New SPECTREM study findings reveal TREMFYA® (guselkumab) effectively clears overlooked and undertreated plaque psoriasis

TREMFYA® (guselkumab) is the first and only IL-23 inhibitor to demonstrate robust results with a fully subcutaneous regimen in both induction and maintenance in Crohn's disease

Empower 2024 Delivers Groundbreaking Insights and Innovation to Achieve Data-Driven Healthcare

Comments

Johnson & Johnson

Johnson & Johnson (JNJ) オプション

Johnson & Johnson (NYSE:JNJ) 株価情報, オプションチェーン

ニュース

パートナーシップ

ベンジンガ・グローバル